{
  "id": 21293871,
  "title": "Invivyd to announce Phase 3 COVID-19 trial results Monday",
  "url": "https://urgent.news/2026/11/22/invivyd-to-announce-phase-3-covid-19-trial-results-monday",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-22T21:24:38.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/invivyd-to-announce-phase-3-covid19-trial-results-monday-93CH-5044129"
  },
  "original_language": "en",
  "account": null,
  "summary": "Invivyd, Inc. (NASDAQ:IVVD) is set to announce the results of its Phase 3 clinical trial for VYD2311, a monoclonal antibody candidate designed to treat COVID-19, on Monday, November 23, 2026. The company will host an investor call at 8:30 a.m. ET following the announcement, which is expected to be made at 7:00 a.m. ET. VYD2311, developed using Invivyd’s technology platform, shares a similar antibody backbone with pemivibart and adintrevimab, both of which have received emergency use authorization for specific COVID-19 treatments. The trial results will be made available on the company’s investor website via a webcast replay approximately two hours after the call concludes.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}